Seroprevalencia para sars-cov2 en pacientes del Hospital Distrital de El Porvenir Santa Isabel durante la emergencia sanitaria marzo 2020-2021
No Thumbnail Available
Date
2022
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Nacional de Trujillo
Abstract
En diciembre de 2019, surgió un coronavirus, al que se denominó SARS-CoV-2, que en los primeros meses de 2020 se extendió por todo el mundo con características de pandemia esto debido a su número básico de propagación (Ro) elevado y la completa susceptibilidad de la población. Esta enfermedad causada por el virus SARS-CoV-2 fue registrada por primera vez en territorio peruano el 7 de marzo de 2020, y el 15 de Marzo en la Libertad. Los escasos estudios de prevalencia, indican la necesidad de efectuar dichos análisis para conocer el avance de la enfermedad en la población, por ello, el objetivo de investigación fue evaluar la seroprevalencia para SARS CoV2 en pacientes del Hospital Distrital de El Porvenir Santa Isabel durante la emergencia sanitaria Junio 2020-2021. Para el desarrollo de este trabajo se registró 6215 como totalidad de pacientes atendidos; descripción, validación previa de la prueba de tamizaje y un análisis estadístico; así, esperar evidenciar en periodos establecidos del año de estudio, que se obtuvo como resultado 43.00% y una seroprevalencia mensual media de 43.83% durante el año de estudio
In December 2019, a coronavirus emerged, called SARS-CoV-2, which in the first months of 2020 spread worldwide with pandemic characteristics this due to its high basic spread number (Ro) and the complete susceptibility of the population. This disease caused by the SARS-CoV-2 virus was first recorded in Peru on March 7, 2020, and on March 15 in Freedom. The few prevalence studies, indicate the need to carry out such analyses to know the progress of the disease in the population, Therefore, the research objective was to evaluate the seroprevalence for SARS CoV2 in patients of the District Hospital of El Porvenir Santa Isabel during the health emergency June 2020-2021. For the development of this study, 6215 were recorded as all patients treated; description, prior validation of the screening test and a statistical analysis; thus, expect to be evidenced in established periods of the study year, which resulted in 43.00% and an average monthly seroprevalence of 43.83% during the study year.
In December 2019, a coronavirus emerged, called SARS-CoV-2, which in the first months of 2020 spread worldwide with pandemic characteristics this due to its high basic spread number (Ro) and the complete susceptibility of the population. This disease caused by the SARS-CoV-2 virus was first recorded in Peru on March 7, 2020, and on March 15 in Freedom. The few prevalence studies, indicate the need to carry out such analyses to know the progress of the disease in the population, Therefore, the research objective was to evaluate the seroprevalence for SARS CoV2 in patients of the District Hospital of El Porvenir Santa Isabel during the health emergency June 2020-2021. For the development of this study, 6215 were recorded as all patients treated; description, prior validation of the screening test and a statistical analysis; thus, expect to be evidenced in established periods of the study year, which resulted in 43.00% and an average monthly seroprevalence of 43.83% during the study year.
Description
Keywords
SARS-COV2, seroprevalencia, prueba rápida serológica, COVID-19, comorbilidad